SI3030575T1 - Modulokini na osnovi IL-15 in IL-15R-alfa sushi domene - Google Patents
Modulokini na osnovi IL-15 in IL-15R-alfa sushi domeneInfo
- Publication number
- SI3030575T1 SI3030575T1 SI201430898T SI201430898T SI3030575T1 SI 3030575 T1 SI3030575 T1 SI 3030575T1 SI 201430898 T SI201430898 T SI 201430898T SI 201430898 T SI201430898 T SI 201430898T SI 3030575 T1 SI3030575 T1 SI 3030575T1
- Authority
- SI
- Slovenia
- Prior art keywords
- modulokines
- domain based
- sushi domain
- alpha sushi
- alpha
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2086—IL-13 to IL-16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Image Processing (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13003963 | 2013-08-08 | ||
PCT/EP2014/002181 WO2015018528A1 (en) | 2013-08-08 | 2014-08-08 | Il-15 and il-15raplha sushi domain based modulokines |
EP14761280.8A EP3030575B1 (en) | 2013-08-08 | 2014-08-08 | Il-15 and il-15r-alpha sushi domain based modulokines |
Publications (1)
Publication Number | Publication Date |
---|---|
SI3030575T1 true SI3030575T1 (sl) | 2018-11-30 |
Family
ID=48953308
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI201430898T SI3030575T1 (sl) | 2013-08-08 | 2014-08-08 | Modulokini na osnovi IL-15 in IL-15R-alfa sushi domene |
SI201431932T SI3444271T1 (sl) | 2013-08-08 | 2014-08-08 | Modulokini na osnovi IL-15 in IL-15Ralfa sushi domene |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI201431932T SI3444271T1 (sl) | 2013-08-08 | 2014-08-08 | Modulokini na osnovi IL-15 in IL-15Ralfa sushi domene |
Country Status (18)
Country | Link |
---|---|
US (2) | US11273204B2 (sl) |
EP (4) | EP3444271B1 (sl) |
JP (2) | JP6649254B2 (sl) |
KR (2) | KR102364523B1 (sl) |
CN (1) | CN105612175B (sl) |
AU (1) | AU2014304931B2 (sl) |
BR (1) | BR112016002614B8 (sl) |
CA (1) | CA2919725C (sl) |
DK (2) | DK3030575T3 (sl) |
EA (1) | EA031080B1 (sl) |
ES (3) | ES2690046T3 (sl) |
HR (3) | HRP20231437T1 (sl) |
HU (2) | HUE064280T2 (sl) |
MX (1) | MX2016001555A (sl) |
PL (3) | PL3995507T3 (sl) |
PT (2) | PT3444271T (sl) |
SI (2) | SI3030575T1 (sl) |
WO (1) | WO2015018528A1 (sl) |
Families Citing this family (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT2529747T (pt) | 2005-12-02 | 2018-05-09 | Icahn School Med Mount Sinai | Vírus da doença de newcastle quiméricos que apresentam proteínas de superfície não nativas e suas utilizações |
US10851178B2 (en) | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
KR102211837B1 (ko) | 2013-01-14 | 2021-02-03 | 젠코어 인코포레이티드 | 신규한 이형이량체 단백질 |
US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
US9701759B2 (en) | 2013-01-14 | 2017-07-11 | Xencor, Inc. | Heterodimeric proteins |
US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
US20160015760A1 (en) | 2013-03-14 | 2016-01-21 | Icahn School Of Medicine At Mount Sinai | Newcastle disease viruses and uses thereof |
US10106624B2 (en) | 2013-03-15 | 2018-10-23 | Xencor, Inc. | Heterodimeric proteins |
US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
CA3093606A1 (en) | 2013-03-15 | 2014-09-18 | Xencor, Inc. | Heterodimeric proteins for induction of t cells |
JP6857498B2 (ja) | 2014-02-27 | 2021-04-14 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | 癌を処置するための併用方法 |
EP2915569A1 (en) | 2014-03-03 | 2015-09-09 | Cytune Pharma | IL-15/IL-15Ralpha based conjugates purification method |
US9394365B1 (en) | 2014-03-12 | 2016-07-19 | Yeda Research And Development Co., Ltd | Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease |
US10519237B2 (en) | 2014-03-12 | 2019-12-31 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
US10618963B2 (en) | 2014-03-12 | 2020-04-14 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
US10144778B2 (en) | 2014-03-12 | 2018-12-04 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
KR20230022270A (ko) | 2014-03-28 | 2023-02-14 | 젠코어 인코포레이티드 | Cd38 및 cd3에 결합하는 이중특이적 항체 |
EP3223845B1 (en) | 2014-11-26 | 2021-05-19 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cd20 |
US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
JP2017536830A (ja) | 2014-11-26 | 2017-12-14 | ゼンコー・インコーポレイテッドXencor、 Inc. | Cd3及びcd38に結合するヘテロ二量体抗体 |
WO2016105450A2 (en) | 2014-12-22 | 2016-06-30 | Xencor, Inc. | Trispecific antibodies |
WO2016141387A1 (en) | 2015-03-05 | 2016-09-09 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
US20180155439A1 (en) * | 2015-06-10 | 2018-06-07 | Emory University | Compositions and Conjugates Comprising an Interleukin and Polypeptides That Specifically Bind TGF-beta |
JP6800219B2 (ja) | 2015-09-16 | 2020-12-16 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 特異的なインターロイキン−15(il−15)アンタゴニストポリペプチド並びに炎症疾患及び自己免疫疾患の処置のためのその使用 |
MX2018003630A (es) | 2015-10-02 | 2018-08-01 | F Hoffmann La Roche Ag | Anticuerpos biespecificos para pd1 y tim3. |
CN108699136B (zh) | 2015-12-07 | 2022-03-18 | Xencor股份有限公司 | 结合cd3和psma的异二聚抗体 |
US11661455B2 (en) | 2016-02-05 | 2023-05-30 | Orionis Biosciences BV | Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety |
CN109071627B (zh) | 2016-02-05 | 2023-04-04 | 奥里尼斯生物科学私人有限公司 | Cd8结合剂 |
CA3017813C (en) * | 2016-03-17 | 2021-12-07 | Oslo Universitetssykehus Hf | Fusion proteins targeting tumour associated macrophages for treating cancer |
EP3443001A4 (en) | 2016-04-11 | 2020-04-29 | Obsidian Therapeutics, Inc. | REGULATED BIOCIRCUIT SYSTEMS |
AU2017268399B2 (en) | 2016-05-18 | 2023-01-12 | Modernatx, Inc. | mRNA combination therapy for the treatment of cancer |
JP7185530B2 (ja) | 2016-06-13 | 2022-12-07 | トルク セラピューティクス, インコーポレイテッド | 免疫細胞機能を促進するための方法および組成物 |
WO2017218707A2 (en) | 2016-06-14 | 2017-12-21 | Xencor, Inc. | Bispecific checkpoint inhibitor antibodies |
WO2018005706A1 (en) | 2016-06-28 | 2018-01-04 | Xencor, Inc. | Heterodimeric antibodies that bind somatostatin receptor 2 |
US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
US10501543B2 (en) * | 2016-10-14 | 2019-12-10 | Xencor, Inc. | IL15/IL15Rα heterodimeric Fc-fusion proteins |
AU2018247765B2 (en) | 2017-04-03 | 2023-11-23 | F. Hoffmann-La Roche Ag | Immunoconjugates of an Anti-PD-1 antibody with a mutant IL-2 or with IL-15 |
TWI690538B (zh) | 2017-04-05 | 2020-04-11 | 瑞士商赫孚孟拉羅股份公司 | 特異性結合至pd1至lag3的雙特異性抗體 |
AU2018291497A1 (en) | 2017-06-30 | 2020-01-16 | Xencor, Inc. | Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains |
JP7423511B2 (ja) | 2017-08-09 | 2024-01-29 | オリオンズ バイオサイエンス インコーポレイテッド | Pd-1およびpd-l1結合物質 |
EP3665201A4 (en) | 2017-08-09 | 2021-06-02 | Orionis Biosciences, Inc. | CD8 BINDERS |
EP3678701A4 (en) | 2017-09-05 | 2021-12-01 | Torque Therapeutics, Inc. | THERAPEUTIC PROTEIN COMPOSITIONS AND METHOD FOR MANUFACTURING AND USING THEREOF |
US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
US11312770B2 (en) | 2017-11-08 | 2022-04-26 | Xencor, Inc. | Bispecific and monospecific antibodies using novel anti-PD-1 sequences |
KR20200100098A (ko) | 2017-12-19 | 2020-08-25 | 젠코어 인코포레이티드 | 조작된 il-2 fc 융합 단백질 |
TW201938196A (zh) * | 2018-01-18 | 2019-10-01 | 美商南特生物科學股份有限公司 | 融合蛋白擴展 |
PE20201342A1 (es) | 2018-02-28 | 2020-11-25 | Pfizer | Variantes de il-15 y usos de las mismas |
US10982006B2 (en) | 2018-04-04 | 2021-04-20 | Xencor, Inc. | Heterodimeric antibodies that bind fibroblast activation protein |
AU2019256539A1 (en) * | 2018-04-18 | 2020-11-26 | Xencor, Inc. | PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof |
EP3781596A1 (en) * | 2018-04-18 | 2021-02-24 | Xencor, Inc. | Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof |
WO2019204646A1 (en) * | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Lag-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and lag-3 antigen binding domains |
EP3781598A1 (en) | 2018-04-18 | 2021-02-24 | Xencor, Inc. | Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains |
EP3861016A2 (en) | 2018-10-03 | 2021-08-11 | Xencor, Inc. | Il-12 heterodimeric fc-fusion proteins |
KR20210091710A (ko) | 2018-10-12 | 2021-07-22 | 젠코어 인코포레이티드 | PD-1 표적화 IL-15/IL-15Rα Fc 융합 단백질 및 병용요법에서의 이의 용도 |
EP3897853A1 (en) | 2018-12-20 | 2021-10-27 | Xencor, Inc. | Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and nkg2d antigen binding domains |
CA3132185A1 (en) | 2019-03-01 | 2020-09-10 | Xencor, Inc. | Heterodimeric antibodies that bind enpp3 and cd3 |
EP3725370A1 (en) | 2019-04-19 | 2020-10-21 | ImmunoBrain Checkpoint, Inc. | Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease |
MX2021014189A (es) * | 2019-05-20 | 2022-01-06 | Cytune Pharma | Regimenes de dosificacion de agonistas de la il-2/il-15r?y para el tratamiento del cancer o enfermedades infecciosas. |
CN114341179A (zh) * | 2019-08-17 | 2022-04-12 | Igm生物科学股份有限公司 | 多聚体双特异性抗cd123结合分子及其用途 |
CN110478474B (zh) * | 2019-08-21 | 2020-06-02 | 启辰生生物科技(珠海)有限公司 | 免疫调节剂、疫苗、细胞及应用 |
CN116574183A (zh) * | 2019-08-22 | 2023-08-11 | 盛禾(中国)生物制药有限公司 | 多功能抗体、其制备及其用途 |
EP4028413A1 (en) | 2019-09-10 | 2022-07-20 | Obsidian Therapeutics, Inc. | Ca2-il15 fusion proteins for tunable regulation |
RU2753282C2 (ru) | 2019-09-19 | 2021-08-12 | Закрытое Акционерное Общество "Биокад" | ИММУНОЦИТОКИН, ВКЛЮЧАЮЩИЙ ГЕТЕРОДИМЕРНЫЙ БЕЛКОВЫЙ КОМПЛЕКС НА ОСНОВЕ IL-15/IL-15Rα, И ЕГО ПРИМЕНЕНИЕ |
TW202128757A (zh) | 2019-10-11 | 2021-08-01 | 美商建南德克公司 | 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白 |
JP2023502712A (ja) * | 2019-11-21 | 2023-01-25 | インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル) | 抗pd-1/il-15免疫サイトカインによる新しいpd-1標的免疫療法 |
CN110804588B (zh) * | 2019-11-22 | 2020-09-01 | 启辰生生物科技(珠海)有限公司 | 用于协同改善t淋巴细胞性质的组合物及其应用 |
EP3889183A1 (en) * | 2020-04-01 | 2021-10-06 | Pierre Fabre Medicament | A protein complex comprising an immunocytokine |
US11919956B2 (en) | 2020-05-14 | 2024-03-05 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3 |
KR102607909B1 (ko) | 2020-08-19 | 2023-12-01 | 젠코어 인코포레이티드 | 항-cd28 조성물 |
CN116134140A (zh) * | 2020-09-01 | 2023-05-16 | 上海药明生物技术有限公司 | 长效作用的il-15及其用途 |
JP2023550880A (ja) | 2020-10-26 | 2023-12-06 | サイチューン ファーマ | 非黒色腫皮膚癌を治療するためのIL-2/IL-15Rβγアゴニスト |
CA3195627A1 (en) | 2020-10-26 | 2022-05-05 | Stefano FERRARA | Il-2/il-15r.beta..gamma. agonist for treating squamous cell carcinoma |
WO2022192403A1 (en) | 2021-03-09 | 2022-09-15 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cldn6 |
JP2024509274A (ja) | 2021-03-10 | 2024-02-29 | ゼンコア インコーポレイテッド | Cd3及びgpc3に結合するヘテロ二量体抗体 |
WO2023086772A1 (en) | 2021-11-12 | 2023-05-19 | Xencor, Inc. | Bispecific antibodies that bind to b7h3 and nkg2d |
Family Cites Families (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5997856A (en) | 1988-10-05 | 1999-12-07 | Chiron Corporation | Method and compositions for solubilization and stabilization of polypeptides, especially proteins |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5073627A (en) | 1989-08-22 | 1991-12-17 | Immunex Corporation | Fusion proteins comprising GM-CSF and IL-3 |
US5108910A (en) | 1989-08-22 | 1992-04-28 | Immunex Corporation | DNA sequences encoding fusion proteins comprising GM-CSF and IL-3 |
US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
AU6703198A (en) | 1997-03-21 | 1998-10-20 | Brigham And Women's Hospital | Immunotherapeutic ctla-4 binding peptides |
EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
JP3793693B2 (ja) | 1998-12-23 | 2006-07-05 | ファイザー インコーポレーテッド | Ctla−4に対するヒトモノクローナル抗体 |
CN1371416B (zh) | 1999-08-24 | 2012-10-10 | 梅达里克斯公司 | 人ctla-4抗体及其应用 |
IL149701A0 (en) | 2001-05-23 | 2002-11-10 | Pfizer Prod Inc | Use of anti-ctla-4 antibodies |
AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
US6887673B2 (en) | 2002-07-30 | 2005-05-03 | Bristol-Myers Squibb Company | Humanized antibodies against human 4-1BB |
NZ581541A (en) | 2002-10-17 | 2011-07-29 | Genmab As | Human monoclonal antibodies against CD20 |
WO2004056875A1 (en) | 2002-12-23 | 2004-07-08 | Wyeth | Antibodies against pd-1 and uses therefor |
US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
US20050136055A1 (en) | 2003-12-22 | 2005-06-23 | Pfizer Inc | CD40 antibody formulation and methods |
CA2551008C (en) | 2003-12-25 | 2013-10-01 | Kirin Beer Kabushiki Kaisha | Anti-cd40 antibody mutants |
WO2005085282A1 (en) | 2004-02-27 | 2005-09-15 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Il-15 binding site for il15-ralpha and specific il-15 mutants having agonists/antagonists activity |
EP1791868B1 (en) * | 2004-07-01 | 2011-02-23 | Novo Nordisk A/S | Antibodies binding to receptors kir2dl1, -2, 3 but not kir2ds4 and their therapeutic use |
WO2006056875A1 (en) | 2004-11-29 | 2006-06-01 | Pharmacia & Upjohn Company Llc | Thiazepine oxazolidinones as antibacterial agents |
DK1866339T3 (da) | 2005-03-25 | 2013-09-02 | Gitr Inc | GTR-bindende molekyler og anvendelser heraf |
CA2607147C (en) | 2005-05-09 | 2018-07-17 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
PT1899364T (pt) | 2005-05-17 | 2020-05-20 | Univ Connecticut | Composições e métodos para imunomodulação num organismo |
KR100694508B1 (ko) | 2005-05-24 | 2007-03-13 | 울산대학교 산학협력단 | Hbbk4항체를 포함하는 암 질환 치료용 약학조성물및 이를 이용한 암의 면역치료 방법 |
JP5252635B2 (ja) | 2005-07-01 | 2013-07-31 | メダレックス インコーポレーティッド | プログラム死リガンド1(pd−l1)に対するヒトモノクローナル抗体 |
EP1777294A1 (en) | 2005-10-20 | 2007-04-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins |
WO2008076560A2 (en) | 2006-11-15 | 2008-06-26 | Medarex, Inc. | Human monoclonal antibodies to btla and methods of use |
SI2079760T1 (sl) | 2006-12-27 | 2016-11-30 | Emory University | Sestavki in metode za zdravljenje okužb |
PT2160401E (pt) | 2007-05-11 | 2014-10-30 | Altor Bioscience Corp | Moléculas de fusão e variantes de il-15 |
CN104945508B (zh) | 2007-06-18 | 2019-02-22 | 默沙东有限责任公司 | 针对人程序性死亡受体pd-1的抗体 |
NZ703668A (en) | 2007-06-27 | 2016-07-29 | Us Sec Dep Of Health And Human Services | Complexes of il-15 and il-15ralpha and uses thereof |
BRPI0820875B1 (pt) | 2007-12-14 | 2021-10-19 | Bristol-Myers Squibb Company | Molécula de ligação isolada, anticorpo monoclonal humano, composição, molécula de ácido nucleico, vetor e célula hospedeira |
CN104548091A (zh) | 2008-02-11 | 2015-04-29 | 治疗科技公司 | 用于肿瘤治疗的单克隆抗体 |
US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
WO2009135031A1 (en) | 2008-04-30 | 2009-11-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic | Substituted il-15 |
AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
BRPI0917891A2 (pt) | 2008-08-25 | 2015-11-24 | Amplimmune Inc | antagonistas de pd-1 e métodos de utilização dos mesmos |
EP2350129B1 (en) | 2008-08-25 | 2015-06-10 | Amplimmune, Inc. | Compositions of pd-1 antagonists and methods of use |
CA2736816C (en) | 2008-09-12 | 2018-05-22 | Isis Innovation Limited | Pd-1 specific antibodies and uses thereof |
JP2012501670A (ja) | 2008-09-12 | 2012-01-26 | アイシス・イノベーション・リミテッド | Pd−1特異抗体およびその使用 |
EP3133086B1 (en) | 2008-09-26 | 2018-08-01 | Dana-Farber Cancer Institute, Inc. | Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses thereof |
LT4209510T (lt) | 2008-12-09 | 2024-03-12 | F. Hoffmann-La Roche Ag | Anti-pd-l1 antikūnai ir jų panaudojimas t ląstelių funkcijos pagerinimui |
EP2393835B1 (en) | 2009-02-09 | 2017-04-05 | Université d'Aix-Marseille | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
WO2010106051A1 (en) | 2009-03-17 | 2010-09-23 | Universite De La Mediterranee | Btla antibodies and uses thereof |
MX2012001417A (es) | 2009-07-31 | 2012-07-03 | Organon Nv | Anticuerpos completamente humanos para atenuante de linfocitos b y t (btla). |
EP3135294B1 (en) | 2009-08-14 | 2020-06-03 | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services | Use of il-15-il-15 receptor heterodimers to treat lymphopenia |
CN102574924A (zh) | 2009-09-03 | 2012-07-11 | 先灵公司 | 抗-gitr抗体 |
EP2545078A1 (en) | 2010-03-11 | 2013-01-16 | UCB Pharma, S.A. | Pd-1 antibody |
NZ629913A (en) | 2010-08-23 | 2016-01-29 | Univ Texas | Anti-ox40 antibodies and methods of using the same |
AU2011305476B2 (en) | 2010-09-21 | 2016-12-01 | Altor Bioscience Corporation | Multimeric IL-15 soluble fusion molecules and methods of making and using same |
CA2805361A1 (en) | 2010-09-29 | 2012-04-05 | Universite De Liege | Combination of an agonistic anti-cd40 monoclonal antibody or a cd40 ligand and inactivated or attenuated bacteria for use in the treatment and/or prevention of mastitis |
GB201103955D0 (en) | 2011-03-09 | 2011-04-20 | Antitope Ltd | Antibodies |
PT2691112T (pt) | 2011-03-31 | 2018-07-10 | Merck Sharp & Dohme | Formulações estáveis de anticorpos para o recetor pd-1 humano de morte programada e tratamentos relacionados |
DK2699598T3 (en) | 2011-04-19 | 2019-04-23 | Pfizer | COMBINATIONS OF ANTI-4-1BB ANTIBODIES AND ADCC-INducing ANTIBODIES FOR TREATMENT OF CANCER |
CA2833636A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
EP2537933A1 (en) * | 2011-06-24 | 2012-12-26 | Institut National de la Santé et de la Recherche Médicale (INSERM) | An IL-15 and IL-15Ralpha sushi domain based immunocytokines |
WO2013006490A2 (en) | 2011-07-01 | 2013-01-10 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to tim3 |
KR101685262B1 (ko) | 2011-08-23 | 2016-12-21 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 항-ox40 항체 및 이의 사용 방법 |
GB201116092D0 (en) | 2011-09-16 | 2011-11-02 | Bioceros B V | Antibodies and uses thereof |
US20150359853A1 (en) * | 2012-10-24 | 2015-12-17 | Admune Therapeutics Llc | Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes |
CA2909576C (en) | 2013-04-19 | 2023-07-18 | Cytune Pharma | Cytokine derived treatment with reduced vascular leak syndrome |
US9580504B1 (en) | 2013-11-07 | 2017-02-28 | Curetech Ltd. | Pidilizumab monoclonal antibody therapy following stem cell transplantation |
RS62989B9 (sr) | 2014-01-15 | 2022-07-29 | Kadmon Corporation Llc | Imunomodulatorni agensi |
-
2014
- 2014-08-08 DK DK14761280.8T patent/DK3030575T3/en active
- 2014-08-08 AU AU2014304931A patent/AU2014304931B2/en active Active
- 2014-08-08 DK DK18177685.7T patent/DK3444271T3/da active
- 2014-08-08 ES ES14761280.8T patent/ES2690046T3/es active Active
- 2014-08-08 JP JP2016532265A patent/JP6649254B2/ja active Active
- 2014-08-08 CN CN201480052636.9A patent/CN105612175B/zh active Active
- 2014-08-08 BR BR112016002614A patent/BR112016002614B8/pt active IP Right Grant
- 2014-08-08 ES ES21200870T patent/ES2963591T3/es active Active
- 2014-08-08 PL PL21200870.0T patent/PL3995507T3/pl unknown
- 2014-08-08 EA EA201690333A patent/EA031080B1/ru unknown
- 2014-08-08 EP EP18177685.7A patent/EP3444271B1/en active Active
- 2014-08-08 CA CA2919725A patent/CA2919725C/en active Active
- 2014-08-08 EP EP23191780.8A patent/EP4269441A3/en active Pending
- 2014-08-08 MX MX2016001555A patent/MX2016001555A/es active IP Right Grant
- 2014-08-08 WO PCT/EP2014/002181 patent/WO2015018528A1/en active Application Filing
- 2014-08-08 PL PL18177685T patent/PL3444271T3/pl unknown
- 2014-08-08 HU HUE21200870A patent/HUE064280T2/hu unknown
- 2014-08-08 PL PL14761280T patent/PL3030575T3/pl unknown
- 2014-08-08 HU HUE18177685A patent/HUE057598T2/hu unknown
- 2014-08-08 PT PT181776857T patent/PT3444271T/pt unknown
- 2014-08-08 ES ES18177685T patent/ES2902589T3/es active Active
- 2014-08-08 PT PT14761280T patent/PT3030575T/pt unknown
- 2014-08-08 KR KR1020167005428A patent/KR102364523B1/ko active IP Right Grant
- 2014-08-08 HR HRP20231437TT patent/HRP20231437T1/hr unknown
- 2014-08-08 KR KR1020227004968A patent/KR102564207B1/ko active IP Right Grant
- 2014-08-08 US US14/910,475 patent/US11273204B2/en active Active
- 2014-08-08 HR HRP20212023TT patent/HRP20212023T1/hr unknown
- 2014-08-08 SI SI201430898T patent/SI3030575T1/sl unknown
- 2014-08-08 SI SI201431932T patent/SI3444271T1/sl unknown
- 2014-08-08 EP EP14761280.8A patent/EP3030575B1/en active Active
- 2014-08-08 EP EP21200870.0A patent/EP3995507B1/en active Active
-
2018
- 2018-09-13 HR HRP20181472TT patent/HRP20181472T1/hr unknown
-
2020
- 2020-01-16 JP JP2020004814A patent/JP6951479B2/ja active Active
-
2022
- 2022-03-11 US US17/693,132 patent/US20220193199A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20181472T1 (hr) | Il-15 i il-15r-alpha "sushi domain" modulokini | |
HK1218692A1 (zh) | 組合物和食物 | |
HK1220467A1 (zh) | 抗- 抗體及其用途 | |
HK1214969A1 (zh) | 抗- -β抗體及其使用 | |
GB201413354D0 (en) | Compositions and methods | |
EP2953474A4 (en) | COMPOSITIONS AND METHODS | |
GB201317889D0 (en) | Product and use | |
GB201308072D0 (en) | Compositions and methods | |
GB201305277D0 (en) | Novel combination and use | |
GB201315063D0 (en) | Appliances and components therefor | |
HK1214333A1 (zh) | 托架以及使用 | |
IL244214B (en) | Thienopiperidine derivative and its use | |
GB201305813D0 (en) | Compositions and methods | |
GB2518812B (en) | Food Item | |
GB201307989D0 (en) | Novel combinations and use | |
GB201309178D0 (en) | Enzyme and uses thereof | |
GB201320992D0 (en) | Complex and uses thereof | |
GB201311894D0 (en) | Conveyor and conveyor structure | |
GB201410957D0 (en) | Lamp element and lamp | |
GB2515335B (en) | Foodstuff and foodstuff preparation method | |
ZA201601880B (en) | Hetero-transglycosylase and uses thereof | |
GB201318602D0 (en) | Food warmer | |
GB201311696D0 (en) | Assembly and methods | |
GB201304166D0 (en) | CelebQuiff and Instant Quiff | |
GB201301393D0 (en) | Kiddibidet and pottibidet |